Supplementary Table 3 from Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

MLA

Bob T. Li, et al. Supplementary Table 3 from Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Apr. 2023. EBSCOhost, https://doi.org/10.1158/2159-8290.22535036.

APA

Bob T. Li, Gilles Gallant, Takahiro Jikoh, Jasmeet Singh, Masahiro Sugihara, Kaku Saito, Trisha M. Wise-Draper, Kenji Tamura, Charles Redfern, Haeseong Park, Shunji Takahashi, Toshihiko Doi, Pasi A. Jänne, Ian Krop, Hiroji Iwata, & Junji Tsurutani. (2023). Supplementary Table 3 from Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. https://doi.org/10.1158/2159-8290.22535036

Chicago

Bob T. Li, Gilles Gallant, Takahiro Jikoh, Jasmeet Singh, Masahiro Sugihara, Kaku Saito, Trisha M. Wise-Draper, et al. 2023. “Supplementary Table 3 from Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors,” April. doi:10.1158/2159-8290.22535036.